Omada Health, Inc. (OMDA) EBITDA
- 2026-06-30: Basis Reported; EBITDA $5.13M*; Operating income $3.55M; Depreciation and amortization $1.58M*.
- 2026-03-31: Basis Reported; EBITDA -$3.27M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA $4.73M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$1.15M*; Operating income -$2.51M; Depreciation and amortization $1.36M*.
Complete source-backed ebitda history.
- Available history
- 2023-12-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | $5.13M* | $3.55M | $1.58M* | $87.83M | 5.84%* | $146.00K* | $4.01M* | (m) | $14.63M | (m) | $0.00 |
|---|
| 2026-03-31 | Reported | -$3.27M | (m) | (m) | (m) | -4.19% | $78.00K | -$11.83M | (m) | $12.70M | (m) | $0.00 |
|---|
| 2025-12-31 | Reported | $4.73M | (m) | (m) | (m) | 6.23% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | -$1.15M* | -$2.51M | $1.36M* | $68.03M | -1.70%* | $537.00K* | $10.13M* | (m) | $10.30M | (m) | $0.00 |
|---|
| 2025-06-30 | Reported | -$2.99M* | -$4.34M | $1.35M* | $61.37M | -4.88%* | $271.00K* | $2.86M* | (m) | $10.02M | (m) | $0.00 |
|---|
| 2025-03-31 | Reported | -$7.06M | (m) | (m) | (m) | -12.85% | $315.00K | -$16.12M | (m) | $8.81M | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | -$5.82M | (m) | (m) | (m) | -12.13% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$7.29M* | -$8.52M | $1.23M* | $45.52M | -16.03%* | $76.00K* | $1.06M* | (m) | $8.85M | (m) | $0.00 |
|---|
| 2024-06-30 | Reported | (m) | -$10.04M | (m) | $41.21M | (m) | (m) | (m) | (m) | $8.99M | (m) | $0.00 |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | -$6.48M | (m) | (m) | (m) | -2.49% | $1.32M | $18.25M | (m) | $40.68M | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | -$38.85M | (m) | (m) | (m) | -22.88% | $596.00K | -$34.18M | (m) | $35.92M | (m) | $0.00 |
|---|
| 2023-12-31 | Reported | -$61.55M | (m) | (m) | (m) | -50.13% | $416.00K | -$49.74M | (m) | $33.74M | (m) | $0.00 |
|---|